EAST WINDSOR, NJ -- (MARKET WIRE) -- December 14, 2006 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT® drug delivery technology, today announced that its partner, Novartis International Pharmaceutical Ltd. (Novartis), has commenced patient screening for the pivotal Phase 3 clinical trials for NM100060, NexMed's topical treatment for onychomycosis (nail fungus). Additional information regarding the Phase 3 trial is available at http://www.novartisclinicaltrials.com/etrials/DiseaseID95/Toenail-Fungus-clinical-trials.go
